BIAF Registers 497,483 Shares for Resale by Selling Stockholders

bioAffinity Technologies, Inc. filed an S-1 registration statement for the resale of up to 497,483 shares of common stock by selling stockholders. These shares comprise 365,603 warrant shares and 131,880 conversion shares from Series B Convertible Preferred Stock, resulting from anti-dilution adjustments. The company will not receive proceeds from the sale of these shares by selling stockholders, but could receive approximately $1.6 million if all warrants are exercised for cash. BIAF's common stock trades on The Nasdaq Capital Market under the symbol "BIAF", with a last reported sale price of $2.43 on April 29, 2026. The filing also noted recent business developments, including 146% growth in CyPath® Lung diagnostic unit sales in Q1 2026 and the enrollment of the first patient in a new lung cancer clinical trial.